ISRCTN80832026 https://doi.org/10.1186/ISRCTN80832026

Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinomas or squamous cell carcinomas of the esophagus

Submission date 27/01/2006	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 27/01/2006	**Overall study status** Completed	
Last Edited 02/07/2009	**Condition category** Cancer	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr A. Gaast, van der

Contact details
Erasmus Medical Center
Department of Medical Oncology
P.O. Box 5201
Rotterdam
Netherlands
3008 AE

Additional identifiers

Protocol serial number
NTR487; EMC 03-209 (CKTO 2004-13)

Study information

Scientific Title

Acronym
CROSS II

Study objectives
Surgery is the standard therapy for esophageal cancer. However, 30% of the resections are irradical. It is thought that preceding chemoradiotherapy will improve the surgery results.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Received from the local medical ethics committee

Primary study design
Interventional

Study design
Multicentre randomised active controlled parallel group trial

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Esophageal cancer

Interventions
Paclitaxel 50 mg/m2 and carboplatin AUC = 2 on days 2, 8, 15, 22 and 29.
Radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week.
Surgery (if randomised in this arm) will preferably be performed within 6 weeks after completion of chemoradiation.

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Paclitaxel, carboplatin

Primary outcome(s)
1. To compare median survival rates between patients treated for surgical resectable esophageal adenocarcinoma or squamous cell carcinoma
2. To compare quality of life before, during and after treatment

Key secondary outcome(s)

1. To compare pathological responses
2. Progression free survival
3. Number of R0 resections
4. Treatment toxicity
5. Costs

Completion date
01/01/2006

Eligibility

Key inclusion criteria
1. Age >18, <75 years
2. Surgical resectable T2-3, N0-1, M0
3. Tumour length longitudinal <8 cm and radial <5 cm
4. No invasion tracheobronchial tree
5. Tumour must not extend more than 2 cm into the stomach
6. ECOG 0-2

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Not Specified

Sex
Not Specified

Key exclusion criteria
1. T1N1
2. T1N0
3. Past or current history of malignancy other than entry diagnosis
4. Previous chemotherapy or radiotherapy
5. MI in last 6 months
6. Congestive heart failure or arrhythmia requiring medication
7. Neurotoxicity grade >1
8. Inadequate caloric and or fluid intake
9. Weight loss 10%

Date of first enrolment
18/03/2004

Date of final enrolment
01/01/2006

Locations

Countries of recruitment
Netherlands

Study participating centre
Erasmus Medical Center
Rotterdam
Netherlands
3008 AE

Sponsor information

Organisation
Erasmus Medical Center, Department of Medical Oncology (Netherlands)

ROR
https://ror.org/018906e22

Funder(s)

Funder type
Charity

Funder Name
Dutch Cancer Society (Netherlands)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	result	01/06/1991		Yes	No